ميلرينون

Amrinone is a phosphodiesterase type 3 inhibitor, similar to milrinone, with positive vasodilator and inotropic properties. Indicated in the treatment of heart failure. Intravenous administration (oral administration has too many side effects).

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weigh and low protein binding) make it likely that it would pass into breast milk in amounts which could be significant.

Milrinone and amrinone have a slower elimination rate in newborns and young infants and a higher risk of potentially serious side effects. ^{(Sanofi 2016, Laitinen 2000, Ramamoorthy 1998)}

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable ^{(Kearney 2018)}, especially during the neonatal period and in the event of prematurity.

If used during lactation: express and discard breast milk and wait to breastfeed 8 to 10 hours after administration.

See below the information of this related product:

• Amrinone (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)